The study aims to evaluate the effects of GLP-1 receptor agonists on mortality and cardiovascular risk in individuals with psoriasis and type 2 diabetes.
Utilized data from TriNetX Research Network
Examined adult populations with psoriasis and type 2 diabetes
Analyzed mortality rates and cardiovascular outcomes
Findings indicate potential reductions in cardiovascular risk associated with GLP-1RA treatment
Results suggest lower mortality rates among treated individuals
Data support a favorable outcome for patients using GLP-1RA therapy
Abstract
The data that support the findings of this study are available from TriNetX Research Network. Restrictions apply to the availability of these data, which were used under licence for this study.